Comparative Efficacy and Risk of Harms of Immediate- versus Extended-Release Second-Generation Antidepressants: A Systematic Review with Network Meta-Analysis View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2014-05-05

AUTHORS

Barbara Nussbaumer, Laura C. Morgan, Ursula Reichenpfader, Amy Greenblatt, Richard A. Hansen, Megan Van Noord, Linda Lux, Bradley N. Gaynes, Gerald Gartlehner

ABSTRACT

BackgroundMajor depressive disorder (MDD) has detrimental effects on an individual’s personal life, leads to increased risk of comorbidities, and places an enormous economic burden on society. Several ‘second-generation’ antidepressants are available as both immediate-release (IR) and extended-release formulations. The advantage of extended-release formulations may be the potentially improved adherence and a lower risk of adverse events.ObjectiveWe conducted a systematic review to assess the comparative efficacy, risk of harms, and patients’ adherence of IR and extended-release antidepressants for the treatment of MDD.Data SourceEnglish-language abstracts were retrieved from PubMed, EMBASE, the Cochrane Library, PsycINFO, and International Pharmaceutical Abstracts from 1980 to October 2012, as well as from reference lists of pertinent review articles and grey literature searches.Eligibility CriteriaWe included head-to-head randomized controlled trials (RCTs) of at least 6 weeks’ duration that compared an IR formulation with an extended-release formulation of the same antidepressant in adult patients with MDD. We also included placebo-controlled trials to conduct a network meta-analysis. To assess harms and adherence, in addition to RCTs, we searched for observational studies with ≥1,000 participants and a follow-up of ≥12 weeks.Study Appraisal and Synthesis MethodsWe dually reviewed abstracts and full texts and assessed quality ratings. Lacking head-to-head evidence for many comparisons of interest, we conducted network meta-analyses using Bayesian methods. Our outcome measure of choice was response on the Hamilton Depression Rating Scale.ResultsWe located seven head-to-head trials and 94 placebo- and active-controlled trials for network meta-analysis. Overall, our analyses indicate that IR and extended-release formulations do not differ substantially with respect to efficacy and risk of harms. The evidence is mixed with respect to differences in adherence, indicating lower adherence for IR formulations.LimitationsThe lack of head-to-head comparisons for many drugs compromises our conclusions. Network meta-analyses have methodological limitations that need to be taken into consideration when interpreting findings.ConclusionAvailable evidence currently shows no clear differences between the two formulations and therefore we cannot recommend a first choice. However, if adherence or compliance with one medication is an issue, then clinicians and patients should consider the alternative medication. If adherence or costs are a problem with one formulation, consideration of the other formulation to provide an adequate treatment trial is reasonable. More... »

PAGES

699-712

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40263-014-0169-z

DOI

http://dx.doi.org/10.1007/s40263-014-0169-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1031746828

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24794101


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antidepressive Agents, Second-Generation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Delayed-Action Preparations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Depressive Disorder, Major", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department for Evidence-Based Medicine and Clinical Epidemiology, Danube University Krems, Dr.-Karl-Dorrek Strasse 30, 3500, Krems, Austria", 
          "id": "http://www.grid.ac/institutes/grid.15462.34", 
          "name": [
            "Department for Evidence-Based Medicine and Clinical Epidemiology, Danube University Krems, Dr.-Karl-Dorrek Strasse 30, 3500, Krems, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nussbaumer", 
        "givenName": "Barbara", 
        "id": "sg:person.0733117013.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733117013.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Triangle Institute International, 3040 Cornwallis Road, PO Box 12194, 27709, Research Triangle Park, NC, USA", 
          "id": "http://www.grid.ac/institutes/grid.62562.35", 
          "name": [
            "Research Triangle Institute International, 3040 Cornwallis Road, PO Box 12194, 27709, Research Triangle Park, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morgan", 
        "givenName": "Laura C.", 
        "id": "sg:person.01041162042.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01041162042.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Community Medicine, Department of Medical and Health Sciences, Link\u00f6ping University, SE-581 83, Link\u00f6ping, Sweden", 
          "id": "http://www.grid.ac/institutes/grid.5640.7", 
          "name": [
            "Department for Evidence-Based Medicine and Clinical Epidemiology, Danube University Krems, Dr.-Karl-Dorrek Strasse 30, 3500, Krems, Austria", 
            "Division of Community Medicine, Department of Medical and Health Sciences, Link\u00f6ping University, SE-581 83, Link\u00f6ping, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reichenpfader", 
        "givenName": "Ursula", 
        "id": "sg:person.01045023142.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01045023142.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Triangle Institute International, 3040 Cornwallis Road, PO Box 12194, 27709, Research Triangle Park, NC, USA", 
          "id": "http://www.grid.ac/institutes/grid.62562.35", 
          "name": [
            "Research Triangle Institute International, 3040 Cornwallis Road, PO Box 12194, 27709, Research Triangle Park, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Greenblatt", 
        "givenName": "Amy", 
        "id": "sg:person.01300022413.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300022413.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Auburn University Harrison School of Pharmacy, 022 James E. Foy Hall, 36849, Auburn, AL, USA", 
          "id": "http://www.grid.ac/institutes/grid.252546.2", 
          "name": [
            "Auburn University Harrison School of Pharmacy, 022 James E. Foy Hall, 36849, Auburn, AL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hansen", 
        "givenName": "Richard A.", 
        "id": "sg:person.0717203466.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717203466.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department for Evidence-Based Medicine and Clinical Epidemiology, Danube University Krems, Dr.-Karl-Dorrek Strasse 30, 3500, Krems, Austria", 
          "id": "http://www.grid.ac/institutes/grid.15462.34", 
          "name": [
            "Department for Evidence-Based Medicine and Clinical Epidemiology, Danube University Krems, Dr.-Karl-Dorrek Strasse 30, 3500, Krems, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Van Noord", 
        "givenName": "Megan", 
        "id": "sg:person.01223523642.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01223523642.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Triangle Institute International, 3040 Cornwallis Road, PO Box 12194, 27709, Research Triangle Park, NC, USA", 
          "id": "http://www.grid.ac/institutes/grid.62562.35", 
          "name": [
            "Research Triangle Institute International, 3040 Cornwallis Road, PO Box 12194, 27709, Research Triangle Park, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lux", 
        "givenName": "Linda", 
        "id": "sg:person.01230124647.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230124647.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Psychiatry, University of North Carolina School of Medicine, Suite 304, Room J, MacNider Building, 27599-7160, Chapel Hill, NC, USA", 
          "id": "http://www.grid.ac/institutes/grid.10698.36", 
          "name": [
            "Department of Psychiatry, University of North Carolina School of Medicine, Suite 304, Room J, MacNider Building, 27599-7160, Chapel Hill, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gaynes", 
        "givenName": "Bradley N.", 
        "id": "sg:person.01220514245.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220514245.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Triangle Institute International, 3040 Cornwallis Road, PO Box 12194, 27709, Research Triangle Park, NC, USA", 
          "id": "http://www.grid.ac/institutes/grid.62562.35", 
          "name": [
            "Department for Evidence-Based Medicine and Clinical Epidemiology, Danube University Krems, Dr.-Karl-Dorrek Strasse 30, 3500, Krems, Austria", 
            "Research Triangle Institute International, 3040 Cornwallis Road, PO Box 12194, 27709, Research Triangle Park, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gartlehner", 
        "givenName": "Gerald", 
        "id": "sg:person.0724733442.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0724733442.73"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00213-010-1822-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038684183", 
          "https://doi.org/10.1007/s00213-010-1822-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00044011-200727070-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046419932", 
          "https://doi.org/10.2165/00044011-200727070-00005"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00019053-200927060-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035738910", 
          "https://doi.org/10.2165/00019053-200927060-00006"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1016/s0893-133x(00)00249-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007098081", 
          "https://doi.org/10.1016/s0893-133x(00)00249-9"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-05-05", 
    "datePublishedReg": "2014-05-05", 
    "description": "BackgroundMajor depressive disorder (MDD) has detrimental effects on an individual\u2019s personal life, leads to increased risk of comorbidities, and places an enormous economic burden on society. Several \u2018second-generation\u2019 antidepressants are available as both immediate-release (IR) and extended-release formulations. The advantage of extended-release formulations may be the potentially improved adherence and a lower risk of adverse events.ObjectiveWe conducted a systematic review to assess the comparative efficacy, risk of harms, and patients\u2019 adherence of IR and extended-release antidepressants for the treatment of MDD.Data SourceEnglish-language abstracts were retrieved from PubMed, EMBASE, the Cochrane Library, PsycINFO, and International Pharmaceutical Abstracts from 1980 to October 2012, as well as from reference lists of pertinent review articles and grey literature searches.Eligibility CriteriaWe included head-to-head randomized controlled trials (RCTs) of at least 6\u00a0weeks\u2019 duration that compared an IR formulation with an extended-release formulation of the same antidepressant in adult patients with MDD. We also included placebo-controlled trials to conduct a network meta-analysis. To assess harms and adherence, in addition to RCTs, we searched for observational studies with \u22651,000 participants and a follow-up of \u226512\u00a0weeks.Study Appraisal and Synthesis MethodsWe dually reviewed abstracts and full texts and assessed quality ratings. Lacking head-to-head evidence for many comparisons of interest, we conducted network meta-analyses using Bayesian methods. Our outcome measure of choice was response on the Hamilton Depression Rating Scale.ResultsWe located seven head-to-head trials and 94 placebo- and active-controlled trials for network meta-analysis. Overall, our analyses indicate that IR and extended-release formulations do not differ substantially with respect to efficacy and risk of harms. The evidence is mixed with respect to differences in adherence, indicating lower adherence for IR formulations.LimitationsThe lack of head-to-head comparisons for many drugs compromises our conclusions. Network meta-analyses have methodological limitations that need to be taken into consideration when interpreting findings.ConclusionAvailable evidence currently shows no clear differences between the two formulations and therefore we cannot recommend a first choice. However, if adherence or compliance with one medication is an issue, then clinicians and patients should consider the alternative medication. If adherence or costs are a problem with one formulation, consideration of the other formulation to provide an adequate treatment trial is reasonable.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40263-014-0169-z", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1111875", 
        "issn": [
          "1172-7047", 
          "1179-1934"
        ], 
        "name": "CNS Drugs", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "28"
      }
    ], 
    "keywords": [
      "extended-release formulation", 
      "risk of harm", 
      "IR formulation", 
      "comparative efficacy", 
      "systematic review", 
      "Hamilton Depression Rating Scale", 
      "adequate treatment trials", 
      "risk of comorbidities", 
      "placebo-controlled trial", 
      "Network Meta-Analysis", 
      "treatment of MDD", 
      "International Pharmaceutical Abstracts", 
      "Depression Rating Scale", 
      "pertinent review articles", 
      "enormous economic burden", 
      "extended-release formulation", 
      "grey literature search", 
      "same antidepressant", 
      "head trials", 
      "adverse events", 
      "adult patients", 
      "alternative medications", 
      "head evidence", 
      "Cochrane Library", 
      "treatment trials", 
      "depressive disorder", 
      "low adherence", 
      "ConclusionAvailable evidence", 
      "STUDY APPRAISAL", 
      "generation antidepressants", 
      "observational study", 
      "outcome measures", 
      "lower risk", 
      "reference lists", 
      "Synthesis MethodsWe", 
      "economic burden", 
      "antidepressants", 
      "head comparison", 
      "Meta-Analysis", 
      "reviewed abstracts", 
      "literature search", 
      "patients", 
      "first choice", 
      "Rating Scale", 
      "trials", 
      "comparisons of interest", 
      "adherence", 
      "medications", 
      "efficacy", 
      "risk", 
      "full text", 
      "weeks", 
      "methodological limitations", 
      "review article", 
      "MDD", 
      "harm", 
      "head", 
      "detrimental effects", 
      "placebo", 
      "comorbidities", 
      "EMBASE", 
      "evidence", 
      "review", 
      "RCTs", 
      "PubMed", 
      "MethodsWe", 
      "clinicians", 
      "ObjectiveWe", 
      "PsycINFO", 
      "drugs", 
      "disorders", 
      "quality ratings", 
      "treatment", 
      "differences", 
      "burden", 
      "clear differences", 
      "Immediate", 
      "duration", 
      "conclusion", 
      "participants", 
      "compliance", 
      "ResultsWe", 
      "findings", 
      "response", 
      "study", 
      "life", 
      "measures", 
      "lack", 
      "events", 
      "comparison", 
      "effect", 
      "choice", 
      "ratings", 
      "search", 
      "appraisal", 
      "Abstract", 
      "addition", 
      "list", 
      "seconds", 
      "consideration", 
      "personal life", 
      "scale", 
      "analysis", 
      "formulation", 
      "respect", 
      "limitations", 
      "library", 
      "article", 
      "society", 
      "method", 
      "interest", 
      "issues", 
      "cost", 
      "advantages", 
      "IR", 
      "problem", 
      "Bayesian methods", 
      "network", 
      "text", 
      "adherence of IR", 
      "extended-release antidepressants", 
      "Data SourceEnglish-language abstracts", 
      "SourceEnglish-language abstracts", 
      "Pharmaceutical Abstracts", 
      "Eligibility CriteriaWe", 
      "CriteriaWe", 
      "LimitationsThe lack", 
      "Extended-Release Second"
    ], 
    "name": "Comparative Efficacy and Risk of Harms of Immediate- versus Extended-Release Second-Generation Antidepressants: A Systematic Review with Network Meta-Analysis", 
    "pagination": "699-712", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1031746828"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40263-014-0169-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24794101"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40263-014-0169-z", 
      "https://app.dimensions.ai/details/publication/pub.1031746828"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_648.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40263-014-0169-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40263-014-0169-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40263-014-0169-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40263-014-0169-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40263-014-0169-z'


 

This table displays all metadata directly associated to this object as RDF triples.

299 TRIPLES      22 PREDICATES      162 URIs      150 LITERALS      13 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40263-014-0169-z schema:about N0cb52a6ac52947cab6751b19f7d380d6
2 N2133a3647a3a4135b594eae16729eb24
3 N3f9f8b672148451a99cec1fe2d1f004a
4 N58e62c6bbfb44d918b768e367f077b08
5 Ncceb0722cdea455b8ba0e51deee52d9e
6 Nf060d25bab234524a7bda51e6c1ec927
7 anzsrc-for:11
8 anzsrc-for:1103
9 schema:author N685b26cac4974149af0d297414a291a9
10 schema:citation sg:pub.10.1007/s00213-010-1822-y
11 sg:pub.10.1016/s0893-133x(00)00249-9
12 sg:pub.10.2165/00019053-200927060-00006
13 sg:pub.10.2165/00044011-200727070-00005
14 schema:datePublished 2014-05-05
15 schema:datePublishedReg 2014-05-05
16 schema:description BackgroundMajor depressive disorder (MDD) has detrimental effects on an individual’s personal life, leads to increased risk of comorbidities, and places an enormous economic burden on society. Several ‘second-generation’ antidepressants are available as both immediate-release (IR) and extended-release formulations. The advantage of extended-release formulations may be the potentially improved adherence and a lower risk of adverse events.ObjectiveWe conducted a systematic review to assess the comparative efficacy, risk of harms, and patients’ adherence of IR and extended-release antidepressants for the treatment of MDD.Data SourceEnglish-language abstracts were retrieved from PubMed, EMBASE, the Cochrane Library, PsycINFO, and International Pharmaceutical Abstracts from 1980 to October 2012, as well as from reference lists of pertinent review articles and grey literature searches.Eligibility CriteriaWe included head-to-head randomized controlled trials (RCTs) of at least 6 weeks’ duration that compared an IR formulation with an extended-release formulation of the same antidepressant in adult patients with MDD. We also included placebo-controlled trials to conduct a network meta-analysis. To assess harms and adherence, in addition to RCTs, we searched for observational studies with ≥1,000 participants and a follow-up of ≥12 weeks.Study Appraisal and Synthesis MethodsWe dually reviewed abstracts and full texts and assessed quality ratings. Lacking head-to-head evidence for many comparisons of interest, we conducted network meta-analyses using Bayesian methods. Our outcome measure of choice was response on the Hamilton Depression Rating Scale.ResultsWe located seven head-to-head trials and 94 placebo- and active-controlled trials for network meta-analysis. Overall, our analyses indicate that IR and extended-release formulations do not differ substantially with respect to efficacy and risk of harms. The evidence is mixed with respect to differences in adherence, indicating lower adherence for IR formulations.LimitationsThe lack of head-to-head comparisons for many drugs compromises our conclusions. Network meta-analyses have methodological limitations that need to be taken into consideration when interpreting findings.ConclusionAvailable evidence currently shows no clear differences between the two formulations and therefore we cannot recommend a first choice. However, if adherence or compliance with one medication is an issue, then clinicians and patients should consider the alternative medication. If adherence or costs are a problem with one formulation, consideration of the other formulation to provide an adequate treatment trial is reasonable.
17 schema:genre article
18 schema:inLanguage en
19 schema:isAccessibleForFree false
20 schema:isPartOf Na9d3aa347d084201805cb78b94a081fb
21 Nb40ed4c0fd5549f49db12deaf9acd930
22 sg:journal.1111875
23 schema:keywords Abstract
24 Bayesian methods
25 Cochrane Library
26 ConclusionAvailable evidence
27 CriteriaWe
28 Data SourceEnglish-language abstracts
29 Depression Rating Scale
30 EMBASE
31 Eligibility CriteriaWe
32 Extended-Release Second
33 Hamilton Depression Rating Scale
34 IR
35 IR formulation
36 Immediate
37 International Pharmaceutical Abstracts
38 LimitationsThe lack
39 MDD
40 Meta-Analysis
41 MethodsWe
42 Network Meta-Analysis
43 ObjectiveWe
44 Pharmaceutical Abstracts
45 PsycINFO
46 PubMed
47 RCTs
48 Rating Scale
49 ResultsWe
50 STUDY APPRAISAL
51 SourceEnglish-language abstracts
52 Synthesis MethodsWe
53 addition
54 adequate treatment trials
55 adherence
56 adherence of IR
57 adult patients
58 advantages
59 adverse events
60 alternative medications
61 analysis
62 antidepressants
63 appraisal
64 article
65 burden
66 choice
67 clear differences
68 clinicians
69 comorbidities
70 comparative efficacy
71 comparison
72 comparisons of interest
73 compliance
74 conclusion
75 consideration
76 cost
77 depressive disorder
78 detrimental effects
79 differences
80 disorders
81 drugs
82 duration
83 economic burden
84 effect
85 efficacy
86 enormous economic burden
87 events
88 evidence
89 extended-release antidepressants
90 extended-release formulation
91 findings
92 first choice
93 formulation
94 full text
95 generation antidepressants
96 grey literature search
97 harm
98 head
99 head comparison
100 head evidence
101 head trials
102 interest
103 issues
104 lack
105 library
106 life
107 limitations
108 list
109 literature search
110 low adherence
111 lower risk
112 measures
113 medications
114 method
115 methodological limitations
116 network
117 observational study
118 outcome measures
119 participants
120 patients
121 personal life
122 pertinent review articles
123 placebo
124 placebo-controlled trial
125 problem
126 quality ratings
127 ratings
128 reference lists
129 respect
130 response
131 review
132 review article
133 reviewed abstracts
134 risk
135 risk of comorbidities
136 risk of harm
137 same antidepressant
138 scale
139 search
140 seconds
141 society
142 study
143 systematic review
144 text
145 treatment
146 treatment of MDD
147 treatment trials
148 trials
149 weeks
150 schema:name Comparative Efficacy and Risk of Harms of Immediate- versus Extended-Release Second-Generation Antidepressants: A Systematic Review with Network Meta-Analysis
151 schema:pagination 699-712
152 schema:productId N6de1f01361b147029e2219884a6aeba2
153 N7c56619bf9ba45f999f01bb093ad9bef
154 Ncf316c9b84ed4beab73931135cb68e37
155 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031746828
156 https://doi.org/10.1007/s40263-014-0169-z
157 schema:sdDatePublished 2021-11-01T18:23
158 schema:sdLicense https://scigraph.springernature.com/explorer/license/
159 schema:sdPublisher N8554f2ac434749939bd60d87dd7e7339
160 schema:url https://doi.org/10.1007/s40263-014-0169-z
161 sgo:license sg:explorer/license/
162 sgo:sdDataset articles
163 rdf:type schema:ScholarlyArticle
164 N0cb52a6ac52947cab6751b19f7d380d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Depressive Disorder, Major
166 rdf:type schema:DefinedTerm
167 N2133a3647a3a4135b594eae16729eb24 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Randomized Controlled Trials as Topic
169 rdf:type schema:DefinedTerm
170 N393b0ddfa39846ea85c079a8a5c2b5a8 rdf:first sg:person.01045023142.69
171 rdf:rest Nd64c953bda044ae38a35a70833de9cfa
172 N3f9f8b672148451a99cec1fe2d1f004a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Risk
174 rdf:type schema:DefinedTerm
175 N58e62c6bbfb44d918b768e367f077b08 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Humans
177 rdf:type schema:DefinedTerm
178 N685b26cac4974149af0d297414a291a9 rdf:first sg:person.0733117013.53
179 rdf:rest Ne4adcd060e8e481bbd7b6af2bc7048da
180 N6de1f01361b147029e2219884a6aeba2 schema:name dimensions_id
181 schema:value pub.1031746828
182 rdf:type schema:PropertyValue
183 N7c56619bf9ba45f999f01bb093ad9bef schema:name doi
184 schema:value 10.1007/s40263-014-0169-z
185 rdf:type schema:PropertyValue
186 N8554f2ac434749939bd60d87dd7e7339 schema:name Springer Nature - SN SciGraph project
187 rdf:type schema:Organization
188 N8a52ac53d88a4060b9823441cd02a536 rdf:first sg:person.01223523642.05
189 rdf:rest Nf5b9b0ad39f645eb9ae42f2aa4606e2a
190 N9465da9f70c84480a42541de1fcc090b rdf:first sg:person.0724733442.73
191 rdf:rest rdf:nil
192 Na9d3aa347d084201805cb78b94a081fb schema:volumeNumber 28
193 rdf:type schema:PublicationVolume
194 Nb40ed4c0fd5549f49db12deaf9acd930 schema:issueNumber 8
195 rdf:type schema:PublicationIssue
196 Nc5a8fc68b85e40a0b7338e4151050a77 rdf:first sg:person.01220514245.29
197 rdf:rest N9465da9f70c84480a42541de1fcc090b
198 Ncceb0722cdea455b8ba0e51deee52d9e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Delayed-Action Preparations
200 rdf:type schema:DefinedTerm
201 Ncf316c9b84ed4beab73931135cb68e37 schema:name pubmed_id
202 schema:value 24794101
203 rdf:type schema:PropertyValue
204 Nd64c953bda044ae38a35a70833de9cfa rdf:first sg:person.01300022413.49
205 rdf:rest Nfcb3323673d14f6c8d465a65c1e6a15e
206 Ne4adcd060e8e481bbd7b6af2bc7048da rdf:first sg:person.01041162042.03
207 rdf:rest N393b0ddfa39846ea85c079a8a5c2b5a8
208 Nf060d25bab234524a7bda51e6c1ec927 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
209 schema:name Antidepressive Agents, Second-Generation
210 rdf:type schema:DefinedTerm
211 Nf5b9b0ad39f645eb9ae42f2aa4606e2a rdf:first sg:person.01230124647.31
212 rdf:rest Nc5a8fc68b85e40a0b7338e4151050a77
213 Nfcb3323673d14f6c8d465a65c1e6a15e rdf:first sg:person.0717203466.34
214 rdf:rest N8a52ac53d88a4060b9823441cd02a536
215 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
216 schema:name Medical and Health Sciences
217 rdf:type schema:DefinedTerm
218 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
219 schema:name Clinical Sciences
220 rdf:type schema:DefinedTerm
221 sg:journal.1111875 schema:issn 1172-7047
222 1179-1934
223 schema:name CNS Drugs
224 schema:publisher Springer Nature
225 rdf:type schema:Periodical
226 sg:person.01041162042.03 schema:affiliation grid-institutes:grid.62562.35
227 schema:familyName Morgan
228 schema:givenName Laura C.
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01041162042.03
230 rdf:type schema:Person
231 sg:person.01045023142.69 schema:affiliation grid-institutes:grid.5640.7
232 schema:familyName Reichenpfader
233 schema:givenName Ursula
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01045023142.69
235 rdf:type schema:Person
236 sg:person.01220514245.29 schema:affiliation grid-institutes:grid.10698.36
237 schema:familyName Gaynes
238 schema:givenName Bradley N.
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220514245.29
240 rdf:type schema:Person
241 sg:person.01223523642.05 schema:affiliation grid-institutes:grid.15462.34
242 schema:familyName Van Noord
243 schema:givenName Megan
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01223523642.05
245 rdf:type schema:Person
246 sg:person.01230124647.31 schema:affiliation grid-institutes:grid.62562.35
247 schema:familyName Lux
248 schema:givenName Linda
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230124647.31
250 rdf:type schema:Person
251 sg:person.01300022413.49 schema:affiliation grid-institutes:grid.62562.35
252 schema:familyName Greenblatt
253 schema:givenName Amy
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300022413.49
255 rdf:type schema:Person
256 sg:person.0717203466.34 schema:affiliation grid-institutes:grid.252546.2
257 schema:familyName Hansen
258 schema:givenName Richard A.
259 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717203466.34
260 rdf:type schema:Person
261 sg:person.0724733442.73 schema:affiliation grid-institutes:grid.62562.35
262 schema:familyName Gartlehner
263 schema:givenName Gerald
264 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0724733442.73
265 rdf:type schema:Person
266 sg:person.0733117013.53 schema:affiliation grid-institutes:grid.15462.34
267 schema:familyName Nussbaumer
268 schema:givenName Barbara
269 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733117013.53
270 rdf:type schema:Person
271 sg:pub.10.1007/s00213-010-1822-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1038684183
272 https://doi.org/10.1007/s00213-010-1822-y
273 rdf:type schema:CreativeWork
274 sg:pub.10.1016/s0893-133x(00)00249-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007098081
275 https://doi.org/10.1016/s0893-133x(00)00249-9
276 rdf:type schema:CreativeWork
277 sg:pub.10.2165/00019053-200927060-00006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035738910
278 https://doi.org/10.2165/00019053-200927060-00006
279 rdf:type schema:CreativeWork
280 sg:pub.10.2165/00044011-200727070-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046419932
281 https://doi.org/10.2165/00044011-200727070-00005
282 rdf:type schema:CreativeWork
283 grid-institutes:grid.10698.36 schema:alternateName Department of Psychiatry, University of North Carolina School of Medicine, Suite 304, Room J, MacNider Building, 27599-7160, Chapel Hill, NC, USA
284 schema:name Department of Psychiatry, University of North Carolina School of Medicine, Suite 304, Room J, MacNider Building, 27599-7160, Chapel Hill, NC, USA
285 rdf:type schema:Organization
286 grid-institutes:grid.15462.34 schema:alternateName Department for Evidence-Based Medicine and Clinical Epidemiology, Danube University Krems, Dr.-Karl-Dorrek Strasse 30, 3500, Krems, Austria
287 schema:name Department for Evidence-Based Medicine and Clinical Epidemiology, Danube University Krems, Dr.-Karl-Dorrek Strasse 30, 3500, Krems, Austria
288 rdf:type schema:Organization
289 grid-institutes:grid.252546.2 schema:alternateName Auburn University Harrison School of Pharmacy, 022 James E. Foy Hall, 36849, Auburn, AL, USA
290 schema:name Auburn University Harrison School of Pharmacy, 022 James E. Foy Hall, 36849, Auburn, AL, USA
291 rdf:type schema:Organization
292 grid-institutes:grid.5640.7 schema:alternateName Division of Community Medicine, Department of Medical and Health Sciences, Linköping University, SE-581 83, Linköping, Sweden
293 schema:name Department for Evidence-Based Medicine and Clinical Epidemiology, Danube University Krems, Dr.-Karl-Dorrek Strasse 30, 3500, Krems, Austria
294 Division of Community Medicine, Department of Medical and Health Sciences, Linköping University, SE-581 83, Linköping, Sweden
295 rdf:type schema:Organization
296 grid-institutes:grid.62562.35 schema:alternateName Research Triangle Institute International, 3040 Cornwallis Road, PO Box 12194, 27709, Research Triangle Park, NC, USA
297 schema:name Department for Evidence-Based Medicine and Clinical Epidemiology, Danube University Krems, Dr.-Karl-Dorrek Strasse 30, 3500, Krems, Austria
298 Research Triangle Institute International, 3040 Cornwallis Road, PO Box 12194, 27709, Research Triangle Park, NC, USA
299 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...